In respect to risk group classification, 15 cases of AML were reclassified from intermediate to adverse risk after detection of variants in genes RUNX1, ASXL1, and TP53. Prognosis of one patient affected by PMF was reclassified as adverse risk after the detection of variants in ASXL1 and SRSF2. Finally, 44 patients were qualified to be included in clinical trials (22 AML, 13 MDS, three MPN, and six MDS/MPN), due to the presence of variants in FLT3-TKD, IDH1, IDH2, and spliceosome genes. This evidence concerns the gene TP53 and myeloproliferative neoplasm.